Clinical data | |
---|---|
Trade names | Vargatef, Ofev |
Other names | BIBF 1120 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615009 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 4.7% |
Protein binding | 97.8% |
Metabolism | Esterases, glucuronidation |
Elimination half-life | 10–15 hrs |
Excretion | 93% via faeces |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.237.441 |
Chemical and physical data | |
Formula | C31H33N5O4 |
Molar mass | 539.636 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.[5]
In March 2020, it was approved for use in the United States to treat chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).[6] It is the first treatment for this group of fibrosing lung diseases that worsen over time that was approved by the U.S. Food and Drug Administration (FDA).[6]
Common side effects include abdominal pain, vomiting, and diarrhea.[7] It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor.[5]
Ofev was developed by Boehringer Ingelheim. It received U.S. Food and Drug Administration (FDA) approval for use for idiopathic pulmonary fibrosis in 2014 – one of only two drugs available for treating IPF – and numerous studies since have demonstrated its effectiveness in slowing the progressive, terminal lung disease.[8]